ENGN vs. ZYME, ABCL, REPL, COLL, RCKT, EOLS, PHVS, AVBP, COGT, and OCS
Should you be buying enGene stock or one of its competitors? The main competitors of enGene include Zymeworks (ZYME), AbCellera Biologics (ABCL), Replimune Group (REPL), Collegium Pharmaceutical (COLL), Rocket Pharmaceuticals (RCKT), Evolus (EOLS), Pharvaris (PHVS), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry.
enGene vs.
Zymeworks (NYSE:ZYME) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.
Zymeworks currently has a consensus price target of $19.17, suggesting a potential upside of 33.19%. enGene has a consensus price target of $25.89, suggesting a potential upside of 314.69%. Given enGene's stronger consensus rating and higher probable upside, analysts clearly believe enGene is more favorable than Zymeworks.
Zymeworks received 275 more outperform votes than enGene when rated by MarketBeat users. However, 94.44% of users gave enGene an outperform vote while only 67.75% of users gave Zymeworks an outperform vote.
enGene has lower revenue, but higher earnings than Zymeworks. enGene is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.
Zymeworks has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.65, indicating that its share price is 165% less volatile than the S&P 500.
enGene has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. enGene's return on equity of -16.69% beat Zymeworks' return on equity.
92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by company insiders. Comparatively, 13.7% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, enGene had 2 more articles in the media than Zymeworks. MarketBeat recorded 6 mentions for enGene and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.67 beat enGene's score of 0.54 indicating that Zymeworks is being referred to more favorably in the media.
Summary
enGene beats Zymeworks on 11 of the 16 factors compared between the two stocks.
Get enGene News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:ENGN) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ENGN Stock Alerts